In the trial, 38.0% of participants had 4-week continuous abstinence at EOT (weeks 9–12 post-quit). Receiving varenicline, compared to placebo, increased abstinence (53.1% in varenicline arm n=414; 21.3% in placebo arm n=376; OR=4.18, 95% CI=3.05–5.72, df=1, p= 5.5×10−19). Varenicline was associated with abstinence across all three genotype groups (GG: OR=4.65, CI=2.85–7.57, p= 7.0×10−10; GA: OR=3.89, 95% CI=2.44–6.20, df=1, p= 1.0×10−8; AA: OR=3.80, 95% CI=1.56–9.27, df=1, p= 0.0033).
